OrganiGram (OGI)
(Delayed Data from NSDQ)
$1.47 USD
-0.07 (-4.55%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $1.46 -0.01 (-0.68%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.47 USD
-0.07 (-4.55%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $1.46 -0.01 (-0.68%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
Can Product Innovation Aid OrganiGram (OGI) in Q2 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and ongoing product innovation in the fiscal second quarter.
Implied Volatility Surging for Organigram (OGI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Organigram Holdings (OGI) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in OrganiGram (OGI) Stock
by Zacks Equity Research
Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Why Earnings Season Could Be Great for OrganiGram (OGI)
by Zacks Equity Research
OrganiGram (OGI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Implied Volatility Surging for OrganiGram (OGI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.
What's in the Cards for OrganiGram (OGI) in Q4 Earnings?
by Zacks Equity Research
According to OrganiGram (OGI), there is hugely unmet consumer demand for CBD products.
Marijuana Stocks to Buy or Avoid in November
by Tirthankar Chakraborty
We highlight three marijuana stocks that look like solid bargains, while one in particular should be avoided in the near future.
LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View
by Zacks Equity Research
LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.
Organigram (OGI) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Organigram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Options Traders Expect Huge Moves in OrganiGram (OGI) Stock
by Zacks Equity Research
Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.